Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.

[1]  A. Fléchon,et al.  Gemcitabine in bladder cancer , 2007, Expert opinion on pharmacotherapy.

[2]  M. Dimopoulos,et al.  The combination of gemcitabine and carboplatin as first‐line treatment in patients with advanced urothelial carcinoma , 2006, Cancer.

[3]  Sergio Ricci,et al.  Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Bamias,et al.  Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. , 2004, Urology.

[5]  J. Carles,et al.  Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract , 2003, Cancer.

[6]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[7]  H. Gurney,et al.  Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  J. Baselga,et al.  A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. , 2001, European journal of cancer.

[9]  G. Scagliotti,et al.  A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  J. Carles,et al.  Carboplatin-Gemcitabine Treatment of Patients with Transitional Cell Carcinoma of the Bladder and Impaired Renal Function , 2000, Oncology.

[11]  W. Oh,et al.  Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  L. Crinò,et al.  Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  G. Luporini,et al.  Gemcitabine/cisplatin in advanced transitional cell carcinoma of the urinary tract (TCC): a phase II multicenter trial , 1999 .

[14]  I. Tannock,et al.  Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Kuzel,et al.  Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Francis,et al.  Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. , 1996, Gynecologic oncology.

[17]  M. Moore.  Activity of gemcitabine in patients with advanced pancreatic carcinoma: A review , 1996, Cancer.

[18]  F. Shepherd,et al.  Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. , 1996, European journal of cancer.

[19]  G. Peters,et al.  Interaction between cisplatin and gemcitabine in vitro and in vivo. , 1995, Seminars in oncology.

[20]  H. Scher.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, The Journal of urology.

[21]  C. Logothetis,et al.  A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  E Wiltshaw,et al.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  I. Tannock,et al.  M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. , 1989, The Journal of urology.

[24]  R. Kefford,et al.  A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Egorin,et al.  The pharmacology of carboplatin. , 1989, Seminars in oncology.

[26]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[27]  N. Geller,et al.  M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. , 1988, The Journal of urology.

[28]  F. Freiha,et al.  Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[30]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .